Preclinical data from mouse xenograft models suggested that pulsed gefitinib (another EGFR TKI) before paclitaxel caused significantly more tumor regression than continuous gefitinib dosing in combination with paclitaxel [15]. This evidence concerns the gene EGFR and neoplasm.